You are here: Industry Insights > depression

News List

Positive effects of psychedelic microdosing likely due to placebo effect, finds study europeanpharmaceuticalreview
March 04, 2021
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
R-ketamine Demonstrates Tolerability in Phase 1 Single Ascending Dose Study americanpharmaceuticalreview
February 24, 2021
Perception Neuroscience announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine).
Biogen and Sage Therapeutics to co-develop depression and tremor therapies pharmaceutical-technology
December 01, 2020
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.
SMC accepts 14 new medicines for use by NHS Scotland pharmatimes
September 17, 2020
Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.
Neurocrine Licenses Seven Takeda Compounds in $2B Deal contractpharma
June 22, 2020
To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.
Depression, anxiety may be side effects as nation grapples with COVID-19 americanpharmaceuticalreview
April 17, 2020
Millions of Americans are being impacted by the psychological fallout from the COVID-19 pandemic and its economic aftermath, and large numbers may experience emotional distress ...
How to take care of your mental health during the COVID-19 pandemic europeanpharmaceuticalreview
April 02, 2020
During the COVID-19 pandemic, when many are in lockdown or self-isolating, mental health could suffer. This article suggests some ways to stay healthy over this period.
Dr Reddy’s launches generic opioid antagonist injection in US expresspharma
March 23, 2020
The product is a generic version of ADAPT Pharma Operations's Narcan injection.
Denovo Biopharma Announces Breakthrough Discovery of Liafensine for Depression americanpharmaceuticalreview
March 13, 2020
Denovo Biopharma has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform.
COMPASS Granted Patent of Psilocybin Formulation for Treatment-Resistant Depression americanpharmaceuticalreview
January 17, 2020
COMPASS Pathways has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office (USPTO).

Previous page 1 2 3 4 5 6 7 8 9 10 Next page